6185 Stock Overview
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6185 from our risk checks.
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$18.04 |
| 52 Week High | HK$44.05 |
| 52 Week Low | HK$14.80 |
| Beta | 0.58 |
| 1 Month Change | 3.80% |
| 3 Month Change | -2.06% |
| 1 Year Change | -55.40% |
| 3 Year Change | -93.99% |
| 5 Year Change | -55.35% |
| Change since IPO | -48.01% |
Recent News & Updates
Recent updates
The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically
Apr 07
Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?
Feb 06CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
Oct 13Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be
Sep 07CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?
May 12Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?
Jan 09CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up
Sep 16Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade
Aug 31Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?
Aug 29Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts
Jul 13Is CanSino Biologics (HKG:6185) Using Too Much Debt?
Jul 01We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt
Mar 15CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%
Jan 11Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?
Dec 26CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly
Oct 01CanSino Biologics' (HKG:6185) Earnings Aren't As Good As They Appear
Sep 05Is CanSino Biologics (HKG:6185) Using Debt In A Risky Way?
Jul 03We Might See A Profit From CanSino Biologics Inc. (HKG:6185) Soon
Apr 20Shareholder Returns
| 6185 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -2.8% | -6.1% | -2.8% |
| 1Y | -55.4% | -46.6% | -15.0% |
Return vs Industry: 6185 underperformed the Hong Kong Biotechs industry which returned -47.1% over the past year.
Return vs Market: 6185 underperformed the Hong Kong Market which returned -16.4% over the past year.
Price Volatility
| 6185 volatility | |
|---|---|
| 6185 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 6185 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6185's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,494 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| 6185 fundamental statistics | |
|---|---|
| Market cap | HK$8.25b |
| Earnings (TTM) | -HK$1.60b |
| Revenue (TTM) | HK$386.35m |
11.5x
P/S Ratio-2.8x
P/E RatioIs 6185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6185 income statement (TTM) | |
|---|---|
| Revenue | CN¥357.08m |
| Cost of Revenue | CN¥800.83m |
| Gross Profit | -CN¥443.75m |
| Other Expenses | CN¥1.04b |
| Earnings | -CN¥1.48b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -6.00 |
| Gross Margin | -124.27% |
| Net Profit Margin | -415.23% |
| Debt/Equity Ratio | 46.5% |
How did 6185 perform over the long term?
See historical performance and comparison